nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—testicular cancer	0.42	1	CrCtD
Pralatrexate—SLC19A1—Methotrexate—testicular cancer	0.111	0.426	CbGbCtD
Pralatrexate—FPGS—Methotrexate—testicular cancer	0.0803	0.308	CbGbCtD
Pralatrexate—Raltitrexed—Methotrexate—testicular cancer	0.0555	0.2	CrCrCtD
Pralatrexate—Pemetrexed—Methotrexate—testicular cancer	0.0555	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—testicular cancer	0.0555	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—testicular cancer	0.0555	0.2	CrCrCtD
Pralatrexate—Folic Acid—Methotrexate—testicular cancer	0.0555	0.2	CrCrCtD
Pralatrexate—DHFR—Methotrexate—testicular cancer	0.0408	0.156	CbGbCtD
Pralatrexate—TYMS—Methotrexate—testicular cancer	0.0284	0.109	CbGbCtD
Pralatrexate—SLC19A1—gonad—testicular cancer	0.00161	0.119	CbGeAlD
Pralatrexate—FPGS—seminal vesicle—testicular cancer	0.00149	0.109	CbGeAlD
Pralatrexate—Renal failure chronic—Ifosfamide—testicular cancer	0.00118	0.0423	CcSEcCtD
Pralatrexate—SLC19A1—testis—testicular cancer	0.00116	0.0855	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Ifosfamide—testicular cancer	0.00115	0.041	CcSEcCtD
Pralatrexate—DHFR—embryo—testicular cancer	0.00103	0.0756	CbGeAlD
Pralatrexate—Renal failure chronic—Cisplatin—testicular cancer	0.00102	0.0365	CcSEcCtD
Pralatrexate—DHFR—seminal vesicle—testicular cancer	0.000967	0.071	CbGeAlD
Pralatrexate—FPGS—female gonad—testicular cancer	0.000874	0.0642	CbGeAlD
Pralatrexate—SLC19A1—lymph node—testicular cancer	0.000843	0.062	CbGeAlD
Pralatrexate—FPGS—testis—testicular cancer	0.000775	0.057	CbGeAlD
Pralatrexate—TYMS—gonad—testicular cancer	0.000706	0.0518	CbGeAlD
Pralatrexate—DHFR—gonad—testicular cancer	0.000699	0.0513	CbGeAlD
Pralatrexate—TYMS—female gonad—testicular cancer	0.000573	0.0421	CbGeAlD
Pralatrexate—DHFR—female gonad—testicular cancer	0.000568	0.0417	CbGeAlD
Pralatrexate—Neoplasm malignant—Chlorambucil—testicular cancer	0.000563	0.0202	CcSEcCtD
Pralatrexate—FPGS—lymph node—testicular cancer	0.000562	0.0413	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Methotrexate—testicular cancer	0.000542	0.0194	CcSEcCtD
Pralatrexate—TYMS—testis—testicular cancer	0.000508	0.0374	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Epirubicin—testicular cancer	0.000507	0.0182	CcSEcCtD
Pralatrexate—DHFR—testis—testicular cancer	0.000503	0.037	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Doxorubicin—testicular cancer	0.000469	0.0168	CcSEcCtD
Pralatrexate—TYMS—Vinorelbine—Vinblastine—testicular cancer	0.000381	0.35	CbGdCrCtD
Pralatrexate—TYMS—Podofilox—Etoposide—testicular cancer	0.000381	0.35	CbGdCrCtD
Pralatrexate—Neoplasm malignant—Ifosfamide—testicular cancer	0.000372	0.0133	CcSEcCtD
Pralatrexate—TYMS—lymph node—testicular cancer	0.000369	0.0271	CbGeAlD
Pralatrexate—DHFR—lymph node—testicular cancer	0.000365	0.0268	CbGeAlD
Pralatrexate—TYMS—Vincristine—Vinblastine—testicular cancer	0.000326	0.3	CbGdCrCtD
Pralatrexate—Toxic epidermal necrolysis—Chlorambucil—testicular cancer	0.000314	0.0113	CcSEcCtD
Pralatrexate—Sepsis—Dactinomycin—testicular cancer	0.000301	0.0108	CcSEcCtD
Pralatrexate—Pancytopenia—Chlorambucil—testicular cancer	0.000286	0.0103	CcSEcCtD
Pralatrexate—Neutropenia—Chlorambucil—testicular cancer	0.000282	0.0101	CcSEcCtD
Pralatrexate—Sepsis—Ifosfamide—testicular cancer	0.000276	0.00988	CcSEcCtD
Pralatrexate—Body temperature increased—Carboplatin—testicular cancer	0.000264	0.00944	CcSEcCtD
Pralatrexate—Pancytopenia—Vinblastine—testicular cancer	0.000262	0.0094	CcSEcCtD
Pralatrexate—Liver function test abnormal—Dactinomycin—testicular cancer	0.000232	0.00833	CcSEcCtD
Pralatrexate—Pain in extremity—Ifosfamide—testicular cancer	0.000231	0.00827	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Dactinomycin—testicular cancer	0.000227	0.00812	CcSEcCtD
Pralatrexate—Pancytopenia—Bleomycin—testicular cancer	0.000222	0.00794	CcSEcCtD
Pralatrexate—Sepsis—Etoposide—testicular cancer	0.000218	0.00781	CcSEcCtD
Pralatrexate—Hypokalaemia—Ifosfamide—testicular cancer	0.00021	0.00752	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Ifosfamide—testicular cancer	0.000208	0.00744	CcSEcCtD
Pralatrexate—Pancytopenia—Dactinomycin—testicular cancer	0.000207	0.00741	CcSEcCtD
Pralatrexate—Neutropenia—Dactinomycin—testicular cancer	0.000204	0.00729	CcSEcCtD
Pralatrexate—Anaemia—Chlorambucil—testicular cancer	0.000194	0.00696	CcSEcCtD
Pralatrexate—Pancytopenia—Ifosfamide—testicular cancer	0.000189	0.00679	CcSEcCtD
Pralatrexate—Leukopenia—Chlorambucil—testicular cancer	0.000188	0.00674	CcSEcCtD
Pralatrexate—Dehydration—Cisplatin—testicular cancer	0.000185	0.00663	CcSEcCtD
Pralatrexate—Hypokalaemia—Cisplatin—testicular cancer	0.000181	0.00649	CcSEcCtD
Pralatrexate—Anaemia—Vinblastine—testicular cancer	0.000178	0.00638	CcSEcCtD
Pralatrexate—Leukopenia—Vinblastine—testicular cancer	0.000172	0.00617	CcSEcCtD
Pralatrexate—Thrombocytopenia—Chlorambucil—testicular cancer	0.000168	0.00601	CcSEcCtD
Pralatrexate—Neoplasm malignant—Epirubicin—testicular cancer	0.000165	0.0059	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.000164	0.00588	CcSEcCtD
Pralatrexate—Anorexia—Chlorambucil—testicular cancer	0.000163	0.00586	CcSEcCtD
Pralatrexate—Pancytopenia—Cisplatin—testicular cancer	0.000163	0.00585	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vinblastine—testicular cancer	0.000154	0.00551	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—testicular cancer	0.000152	0.00546	CcSEcCtD
Pralatrexate—Anaemia—Bleomycin—testicular cancer	0.00015	0.00538	CcSEcCtD
Pralatrexate—Anorexia—Vinblastine—testicular cancer	0.00015	0.00537	CcSEcCtD
Pralatrexate—Pancytopenia—Etoposide—testicular cancer	0.00015	0.00536	CcSEcCtD
Pralatrexate—Decreased appetite—Chlorambucil—testicular cancer	0.000149	0.00534	CcSEcCtD
Pralatrexate—Fatigue—Chlorambucil—testicular cancer	0.000148	0.0053	CcSEcCtD
Pralatrexate—Neutropenia—Etoposide—testicular cancer	0.000147	0.00528	CcSEcCtD
Pralatrexate—Leukopenia—Bleomycin—testicular cancer	0.000146	0.00521	CcSEcCtD
Pralatrexate—Cough—Bleomycin—testicular cancer	0.000142	0.00508	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00014	0.00502	CcSEcCtD
Pralatrexate—Anaemia—Dactinomycin—testicular cancer	0.00014	0.00502	CcSEcCtD
Pralatrexate—Decreased appetite—Vinblastine—testicular cancer	0.000137	0.00489	CcSEcCtD
Pralatrexate—Leukopenia—Dactinomycin—testicular cancer	0.000136	0.00486	CcSEcCtD
Pralatrexate—Body temperature increased—Chlorambucil—testicular cancer	0.000136	0.00486	CcSEcCtD
Pralatrexate—Abdominal pain—Chlorambucil—testicular cancer	0.000136	0.00486	CcSEcCtD
Pralatrexate—Constipation—Vinblastine—testicular cancer	0.000134	0.00481	CcSEcCtD
Pralatrexate—Oedema—Bleomycin—testicular cancer	0.000133	0.00475	CcSEcCtD
Pralatrexate—Sepsis—Methotrexate—testicular cancer	0.00013	0.00468	CcSEcCtD
Pralatrexate—Thrombocytopenia—Bleomycin—testicular cancer	0.00013	0.00466	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vinblastine—testicular cancer	0.000128	0.0046	CcSEcCtD
Pralatrexate—Anaemia—Ifosfamide—testicular cancer	0.000128	0.0046	CcSEcCtD
Pralatrexate—Anorexia—Bleomycin—testicular cancer	0.000126	0.00453	CcSEcCtD
Pralatrexate—Leukopenia—Ifosfamide—testicular cancer	0.000124	0.00446	CcSEcCtD
Pralatrexate—Abdominal pain—Vinblastine—testicular cancer	0.000124	0.00445	CcSEcCtD
Pralatrexate—Oedema—Dactinomycin—testicular cancer	0.000124	0.00443	CcSEcCtD
Pralatrexate—Asthenia—Chlorambucil—testicular cancer	0.000123	0.00441	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—testicular cancer	0.000122	0.00438	CcSEcCtD
Pralatrexate—Pruritus—Chlorambucil—testicular cancer	0.000121	0.00435	CcSEcCtD
Pralatrexate—Cough—Ifosfamide—testicular cancer	0.000121	0.00434	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dactinomycin—testicular cancer	0.000121	0.00434	CcSEcCtD
Pralatrexate—Dyspnoea—Bleomycin—testicular cancer	0.000118	0.00424	CcSEcCtD
Pralatrexate—Anorexia—Dactinomycin—testicular cancer	0.000118	0.00423	CcSEcCtD
Pralatrexate—Diarrhoea—Chlorambucil—testicular cancer	0.000117	0.0042	CcSEcCtD
Pralatrexate—Decreased appetite—Bleomycin—testicular cancer	0.000115	0.00413	CcSEcCtD
Pralatrexate—Oedema—Ifosfamide—testicular cancer	0.000113	0.00406	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—testicular cancer	0.000113	0.00405	CcSEcCtD
Pralatrexate—Asthenia—Vinblastine—testicular cancer	0.000113	0.00404	CcSEcCtD
Pralatrexate—Thrombocytopenia—Ifosfamide—testicular cancer	0.000111	0.00398	CcSEcCtD
Pralatrexate—Anaemia—Cisplatin—testicular cancer	0.000111	0.00397	CcSEcCtD
Pralatrexate—Vomiting—Chlorambucil—testicular cancer	0.000109	0.00391	CcSEcCtD
Pralatrexate—Anorexia—Ifosfamide—testicular cancer	0.000108	0.00387	CcSEcCtD
Pralatrexate—Decreased appetite—Dactinomycin—testicular cancer	0.000108	0.00385	CcSEcCtD
Pralatrexate—Diarrhoea—Vinblastine—testicular cancer	0.000108	0.00385	CcSEcCtD
Pralatrexate—Leukopenia—Cisplatin—testicular cancer	0.000107	0.00384	CcSEcCtD
Pralatrexate—Fatigue—Dactinomycin—testicular cancer	0.000107	0.00382	CcSEcCtD
Pralatrexate—Back pain—Etoposide—testicular cancer	0.000106	0.0038	CcSEcCtD
Pralatrexate—Body temperature increased—Bleomycin—testicular cancer	0.000105	0.00376	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—testicular cancer	0.000102	0.00366	CcSEcCtD
Pralatrexate—Nausea—Chlorambucil—testicular cancer	0.000102	0.00365	CcSEcCtD
Pralatrexate—Anaemia—Etoposide—testicular cancer	0.000101	0.00363	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000101	0.00363	CcSEcCtD
Pralatrexate—Dyspnoea—Ifosfamide—testicular cancer	0.000101	0.00362	CcSEcCtD
Pralatrexate—Liver function test abnormal—Methotrexate—testicular cancer	0.000101	0.00361	CcSEcCtD
Pralatrexate—Vomiting—Vinblastine—testicular cancer	9.99e-05	0.00358	CcSEcCtD
Pralatrexate—Decreased appetite—Ifosfamide—testicular cancer	9.86e-05	0.00353	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—testicular cancer	9.83e-05	0.00352	CcSEcCtD
Pralatrexate—Leukopenia—Etoposide—testicular cancer	9.82e-05	0.00352	CcSEcCtD
Pralatrexate—Abdominal pain—Dactinomycin—testicular cancer	9.78e-05	0.00351	CcSEcCtD
Pralatrexate—Body temperature increased—Dactinomycin—testicular cancer	9.78e-05	0.00351	CcSEcCtD
Pralatrexate—Fatigue—Ifosfamide—testicular cancer	9.78e-05	0.0035	CcSEcCtD
Pralatrexate—Oedema—Cisplatin—testicular cancer	9.78e-05	0.0035	CcSEcCtD
Pralatrexate—Constipation—Ifosfamide—testicular cancer	9.7e-05	0.00347	CcSEcCtD
Pralatrexate—Cough—Etoposide—testicular cancer	9.58e-05	0.00343	CcSEcCtD
Pralatrexate—Thrombocytopenia—Cisplatin—testicular cancer	9.57e-05	0.00343	CcSEcCtD
Pralatrexate—Tachycardia—Cisplatin—testicular cancer	9.54e-05	0.00342	CcSEcCtD
Pralatrexate—Asthenia—Bleomycin—testicular cancer	9.52e-05	0.00341	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—testicular cancer	9.5e-05	0.0034	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—testicular cancer	9.45e-05	0.00339	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—testicular cancer	9.43e-05	0.00338	CcSEcCtD
Pralatrexate—Pruritus—Bleomycin—testicular cancer	9.39e-05	0.00336	CcSEcCtD
Pralatrexate—Nausea—Vinblastine—testicular cancer	9.33e-05	0.00334	CcSEcCtD
Pralatrexate—Anorexia—Cisplatin—testicular cancer	9.32e-05	0.00334	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—testicular cancer	9.3e-05	0.00333	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Ifosfamide—testicular cancer	9.27e-05	0.00332	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—testicular cancer	9.2e-05	0.0033	CcSEcCtD
Pralatrexate—Abdominal pain—Ifosfamide—testicular cancer	8.97e-05	0.00321	CcSEcCtD
Pralatrexate—Body temperature increased—Ifosfamide—testicular cancer	8.97e-05	0.00321	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—testicular cancer	8.96e-05	0.00321	CcSEcCtD
Pralatrexate—Asthenia—Dactinomycin—testicular cancer	8.88e-05	0.00318	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—testicular cancer	8.82e-05	0.00316	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—testicular cancer	8.79e-05	0.00315	CcSEcCtD
Pralatrexate—Thrombocytopenia—Etoposide—testicular cancer	8.77e-05	0.00314	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—testicular cancer	8.77e-05	0.00314	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—testicular cancer	8.74e-05	0.00313	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—testicular cancer	8.73e-05	0.00313	CcSEcCtD
Pralatrexate—Dyspnoea—Cisplatin—testicular cancer	8.72e-05	0.00312	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—testicular cancer	8.6e-05	0.00308	CcSEcCtD
Pralatrexate—Anorexia—Etoposide—testicular cancer	8.54e-05	0.00306	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	8.51e-05	0.00305	CcSEcCtD
Pralatrexate—Decreased appetite—Cisplatin—testicular cancer	8.5e-05	0.00305	CcSEcCtD
Pralatrexate—Diarrhoea—Dactinomycin—testicular cancer	8.47e-05	0.00303	CcSEcCtD
Pralatrexate—Vomiting—Bleomycin—testicular cancer	8.44e-05	0.00302	CcSEcCtD
Pralatrexate—Pancytopenia—Epirubicin—testicular cancer	8.39e-05	0.003	CcSEcCtD
Pralatrexate—Rash—Bleomycin—testicular cancer	8.37e-05	0.003	CcSEcCtD
Pralatrexate—Dermatitis—Bleomycin—testicular cancer	8.36e-05	0.003	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—testicular cancer	8.26e-05	0.00296	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—testicular cancer	8.21e-05	0.00294	CcSEcCtD
Pralatrexate—Asthenia—Ifosfamide—testicular cancer	8.14e-05	0.00292	CcSEcCtD
Pralatrexate—Pruritus—Ifosfamide—testicular cancer	8.02e-05	0.00287	CcSEcCtD
Pralatrexate—Dyspnoea—Etoposide—testicular cancer	7.99e-05	0.00286	CcSEcCtD
Pralatrexate—Epistaxis—Methotrexate—testicular cancer	7.93e-05	0.00284	CcSEcCtD
Pralatrexate—Nausea—Bleomycin—testicular cancer	7.88e-05	0.00282	CcSEcCtD
Pralatrexate—Vomiting—Dactinomycin—testicular cancer	7.87e-05	0.00282	CcSEcCtD
Pralatrexate—Rash—Dactinomycin—testicular cancer	7.8e-05	0.0028	CcSEcCtD
Pralatrexate—Decreased appetite—Etoposide—testicular cancer	7.79e-05	0.00279	CcSEcCtD
Pralatrexate—Diarrhoea—Ifosfamide—testicular cancer	7.76e-05	0.00278	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—testicular cancer	7.76e-05	0.00278	CcSEcCtD
Pralatrexate—Body temperature increased—Cisplatin—testicular cancer	7.73e-05	0.00277	CcSEcCtD
Pralatrexate—Fatigue—Etoposide—testicular cancer	7.72e-05	0.00277	CcSEcCtD
Pralatrexate—Constipation—Etoposide—testicular cancer	7.66e-05	0.00274	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—testicular cancer	7.64e-05	0.00274	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—testicular cancer	7.59e-05	0.00272	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—testicular cancer	7.43e-05	0.00266	CcSEcCtD
Pralatrexate—Nausea—Dactinomycin—testicular cancer	7.35e-05	0.00263	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Etoposide—testicular cancer	7.32e-05	0.00262	CcSEcCtD
Pralatrexate—Vomiting—Ifosfamide—testicular cancer	7.21e-05	0.00258	CcSEcCtD
Pralatrexate—Rash—Ifosfamide—testicular cancer	7.15e-05	0.00256	CcSEcCtD
Pralatrexate—Dermatitis—Ifosfamide—testicular cancer	7.14e-05	0.00256	CcSEcCtD
Pralatrexate—Body temperature increased—Etoposide—testicular cancer	7.08e-05	0.00254	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—testicular cancer	7.08e-05	0.00254	CcSEcCtD
Pralatrexate—Asthenia—Cisplatin—testicular cancer	7.02e-05	0.00251	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—testicular cancer	6.87e-05	0.00246	CcSEcCtD
Pralatrexate—Nausea—Ifosfamide—testicular cancer	6.74e-05	0.00241	CcSEcCtD
Pralatrexate—Diarrhoea—Cisplatin—testicular cancer	6.69e-05	0.0024	CcSEcCtD
Pralatrexate—Asthenia—Etoposide—testicular cancer	6.43e-05	0.0023	CcSEcCtD
Pralatrexate—Back pain—Methotrexate—testicular cancer	6.36e-05	0.00228	CcSEcCtD
Pralatrexate—Pruritus—Etoposide—testicular cancer	6.34e-05	0.00227	CcSEcCtD
Pralatrexate—Vomiting—Cisplatin—testicular cancer	6.22e-05	0.00223	CcSEcCtD
Pralatrexate—Rash—Cisplatin—testicular cancer	6.16e-05	0.00221	CcSEcCtD
Pralatrexate—Dermatitis—Cisplatin—testicular cancer	6.16e-05	0.00221	CcSEcCtD
Pralatrexate—Diarrhoea—Etoposide—testicular cancer	6.13e-05	0.0022	CcSEcCtD
Pralatrexate—Anaemia—Methotrexate—testicular cancer	6.08e-05	0.00218	CcSEcCtD
Pralatrexate—Back pain—Epirubicin—testicular cancer	5.95e-05	0.00213	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—testicular cancer	5.88e-05	0.00211	CcSEcCtD
Pralatrexate—Nausea—Cisplatin—testicular cancer	5.81e-05	0.00208	CcSEcCtD
Pralatrexate—Cough—Methotrexate—testicular cancer	5.74e-05	0.00206	CcSEcCtD
Pralatrexate—Vomiting—Etoposide—testicular cancer	5.7e-05	0.00204	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—testicular cancer	5.69e-05	0.00204	CcSEcCtD
Pralatrexate—Rash—Etoposide—testicular cancer	5.65e-05	0.00202	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—testicular cancer	5.64e-05	0.00202	CcSEcCtD
Pralatrexate—Leukopenia—Epirubicin—testicular cancer	5.51e-05	0.00197	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—testicular cancer	5.51e-05	0.00197	CcSEcCtD
Pralatrexate—Cough—Epirubicin—testicular cancer	5.37e-05	0.00192	CcSEcCtD
Pralatrexate—Nausea—Etoposide—testicular cancer	5.32e-05	0.00191	CcSEcCtD
Pralatrexate—Anaemia—Doxorubicin—testicular cancer	5.26e-05	0.00189	CcSEcCtD
Pralatrexate—Thrombocytopenia—Methotrexate—testicular cancer	5.25e-05	0.00188	CcSEcCtD
Pralatrexate—Anorexia—Methotrexate—testicular cancer	5.11e-05	0.00183	CcSEcCtD
Pralatrexate—Leukopenia—Doxorubicin—testicular cancer	5.1e-05	0.00183	CcSEcCtD
Pralatrexate—Oedema—Epirubicin—testicular cancer	5.02e-05	0.0018	CcSEcCtD
Pralatrexate—Cough—Doxorubicin—testicular cancer	4.97e-05	0.00178	CcSEcCtD
Pralatrexate—Thrombocytopenia—Epirubicin—testicular cancer	4.92e-05	0.00176	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—testicular cancer	4.9e-05	0.00176	CcSEcCtD
Pralatrexate—Anorexia—Epirubicin—testicular cancer	4.79e-05	0.00171	CcSEcCtD
Pralatrexate—Dyspnoea—Methotrexate—testicular cancer	4.78e-05	0.00171	CcSEcCtD
Pralatrexate—Decreased appetite—Methotrexate—testicular cancer	4.66e-05	0.00167	CcSEcCtD
Pralatrexate—Oedema—Doxorubicin—testicular cancer	4.65e-05	0.00166	CcSEcCtD
Pralatrexate—Fatigue—Methotrexate—testicular cancer	4.63e-05	0.00166	CcSEcCtD
Pralatrexate—Thrombocytopenia—Doxorubicin—testicular cancer	4.55e-05	0.00163	CcSEcCtD
Pralatrexate—Tachycardia—Doxorubicin—testicular cancer	4.53e-05	0.00162	CcSEcCtD
Pralatrexate—Dyspnoea—Epirubicin—testicular cancer	4.48e-05	0.0016	CcSEcCtD
Pralatrexate—Anorexia—Doxorubicin—testicular cancer	4.43e-05	0.00159	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Methotrexate—testicular cancer	4.39e-05	0.00157	CcSEcCtD
Pralatrexate—Decreased appetite—Epirubicin—testicular cancer	4.36e-05	0.00156	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—testicular cancer	4.33e-05	0.00155	CcSEcCtD
Pralatrexate—Constipation—Epirubicin—testicular cancer	4.29e-05	0.00154	CcSEcCtD
Pralatrexate—Abdominal pain—Methotrexate—testicular cancer	4.24e-05	0.00152	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—testicular cancer	4.24e-05	0.00152	CcSEcCtD
Pralatrexate—Dyspnoea—Doxorubicin—testicular cancer	4.14e-05	0.00148	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Epirubicin—testicular cancer	4.11e-05	0.00147	CcSEcCtD
Pralatrexate—Decreased appetite—Doxorubicin—testicular cancer	4.04e-05	0.00145	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—testicular cancer	4.01e-05	0.00144	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—testicular cancer	3.97e-05	0.00142	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—testicular cancer	3.97e-05	0.00142	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—testicular cancer	3.97e-05	0.00142	CcSEcCtD
Pralatrexate—Asthenia—Methotrexate—testicular cancer	3.85e-05	0.00138	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Doxorubicin—testicular cancer	3.8e-05	0.00136	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—testicular cancer	3.8e-05	0.00136	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—testicular cancer	3.67e-05	0.00132	CcSEcCtD
Pralatrexate—Body temperature increased—Doxorubicin—testicular cancer	3.67e-05	0.00132	CcSEcCtD
Pralatrexate—Diarrhoea—Methotrexate—testicular cancer	3.67e-05	0.00132	CcSEcCtD
Pralatrexate—Asthenia—Epirubicin—testicular cancer	3.6e-05	0.00129	CcSEcCtD
Pralatrexate—Pruritus—Epirubicin—testicular cancer	3.55e-05	0.00127	CcSEcCtD
Pralatrexate—Diarrhoea—Epirubicin—testicular cancer	3.44e-05	0.00123	CcSEcCtD
Pralatrexate—Vomiting—Methotrexate—testicular cancer	3.41e-05	0.00122	CcSEcCtD
Pralatrexate—Rash—Methotrexate—testicular cancer	3.38e-05	0.00121	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—testicular cancer	3.38e-05	0.00121	CcSEcCtD
Pralatrexate—Asthenia—Doxorubicin—testicular cancer	3.33e-05	0.00119	CcSEcCtD
Pralatrexate—Pruritus—Doxorubicin—testicular cancer	3.29e-05	0.00118	CcSEcCtD
Pralatrexate—Vomiting—Epirubicin—testicular cancer	3.19e-05	0.00114	CcSEcCtD
Pralatrexate—Nausea—Methotrexate—testicular cancer	3.19e-05	0.00114	CcSEcCtD
Pralatrexate—Diarrhoea—Doxorubicin—testicular cancer	3.18e-05	0.00114	CcSEcCtD
Pralatrexate—Rash—Epirubicin—testicular cancer	3.17e-05	0.00113	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—testicular cancer	3.16e-05	0.00113	CcSEcCtD
Pralatrexate—Nausea—Epirubicin—testicular cancer	2.98e-05	0.00107	CcSEcCtD
Pralatrexate—Vomiting—Doxorubicin—testicular cancer	2.95e-05	0.00106	CcSEcCtD
Pralatrexate—Rash—Doxorubicin—testicular cancer	2.93e-05	0.00105	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—testicular cancer	2.93e-05	0.00105	CcSEcCtD
Pralatrexate—Nausea—Doxorubicin—testicular cancer	2.76e-05	0.000989	CcSEcCtD
